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IL-7 promotes T cell proliferation through 
destabilization of p27Kip1
Wen Qing Li,1 Qiong Jiang,1 Eiman Aleem,2 Philipp Kaldis,2 
Annette R. Khaled,1 and Scott K. Durum1
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Interleukin (IL)-7 is required for survival and homeostatic proliferation of T lymphocytes. 
The survival effect of IL-7 is primarily through regulation of Bcl-2 family members; 
  however, the proliferative mechanism is unclear. It has not been determined whether the 
IL-7   receptor actually delivers a proliferative signal or whether, by promoting survival, prolif-
eration results from signals other than the IL-7 receptor. We show that in an IL-7–dependent 
T cell line, cells protected from apoptosis nevertheless underwent cell cycle arrest after IL-7 
withdrawal. This arrest was accompanied by up-regulation of the cyclin-dependent kinase 
inhibitor p27Kip1 through a posttranslational mechanism. Overexpression of p27Kip1 induced 
G1 arrest in the presence of IL-7, whereas knockdown of p27Kip1 by small interfering RNA 
promoted S phase entry after IL-7 withdrawal. CD4 or CD8 T cells transferred into IL-7–
defi  cient hosts   underwent G1 arrest, whereas 27Kip1-defi  cient T cells underwent prolifera-
tion. We observed that IL-7 withdrawal activated protein kinase C (PKC)𝗉 and that 
inhibition of PKC𝗉 with a   pharmacological inhibitor completely blocked the rise of p27Kip1 
and rescued cells from G1 arrest. The conven  tional pathway to breakdown of p27Kip1 is 
mediated by S phase kinase-associated protein 2; however, our evidence suggests that PKC𝗉 
acts via a distinct, unknown pathway inducing G1 arrest after IL-7 withdrawal from T cells. 
Hence, IL-7 maintains T cell proliferation through a novel pathway of p27Kip1 regulation.
The size of the peripheral T cell pool is tightly 
controlled through homeostatic mechanisms 
that regulate cell survival and proliferation. The 
cytokine IL-7, a product of nonlymphoid cells 
in lymphoid tissues, is one of the required stim-
uli for both survival and proliferation of most 
of the major subsets of peripheral T cells (1–7). 
Together with IL-7, weak signals from the 
TCR-recognizing self-peptide/MHC are re-
quired for survival and proliferation of naive 
CD4 and CD8 cells (1, 8, 9). Survival and prolif-
eration of memory CD8 cells depends on IL-15 
and IL-7 (2, 3). Memory CD4 cells become 
acutely dependent on IL-7 for homeostatic pro-
liferation when TCR signaling is abolished (4).
Survival of T cells has been largely attrib-
uted to IL-7 regulation of the balance of pro-
apoptotic versus antiapoptotic members of the 
Bcl-2 family. Thus, IL-7 protects T cells from 
death through the induction of antiapoptotic 
proteins Bcl-2 (10) and Mcl-1 (11), and inhibi-
tion of proapoptotic proteins Bax (12), Bad 
(13), and Bim (14). The proliferative mecha-
nism of T cells in response to IL-7 has not been 
studied extensively. It has not been determined 
whether the IL-7 receptor delivers a prolifera-
tion signal per se, or alternatively whether the 
IL-7 eff  ect is to maintain survival, permitting 
other signals to induce cell division.
As characterized in other cell types, prolif-
eration depends on the activity of a series of 
protein complexes composed of cyclins and 
cyclin-dependent kinases (CDKs; reference 15). 
CDK activity is regulated through phosphory-
lation-dephosphorylation of the kinase subunit 
and in large part through inhibition by CDK 
inhibitors (CKIs; references 15 and 16). CKIs 
can be divided into two classes: inhibitors of 
CDK4 proteins (p16, p15, p18, and p19) and 
inhibitors of the Cip/Kip family (p21Cip1, 
p27Kip1, and p57Kip2). p21Cip1 and p27Kip1 are 
able to constrain a broad spectrum of CDKs 
(16) and are expressed in peripheral T cells 
(17, 18). Mice lacking p27Kip1 display gigantism 
with disproportionately enlarged lymphoid or-
gans as a result of increased cellularity (19–21), 
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suggesting that p27Kip1 could be an inhibitor of homeostatic 
proliferation of T cells. Peripheral T cells from p27Kip1-
  transgenic mice show a dramatically reduced ability to pro-
liferate in response to mitogenic stimulation (22). The role of 
p21Cip1 in T lymphocytes is less clear, with some evidence sug-
gesting that it promotes T lymphocyte apoptosis mediated by 
Fas or protects activated/memory T cells from apoptosis (23).
p27Kip1 plays a pivotal role in the control of cell cycle G1 
to S phase transition by inhibiting the activities of G1 cyclins/
CDKs. In response to stimulation by growth factors, levels of 
p27Kip1 dramatically decrease, which appears to be a critical 
mechanism by which growth factors are capable of inducing 
cell cycle progression. IL-3 repressed p27Kip1 transcription in 
a murine pro–B cell line, Ba/F3 24, as did IL-2 in CTLL cells 
(25). However, in most types of normal or transformed cells, 
p27Kip1 is regulated posttranslationally through ubiquitina-
tion and proteosomal degradation (26). Phosphoryla  tion of 
p27Kip1 at threonine 187 (T187) by CDK2–cyclin E com-
plexes is thought to initiate the major pathway for p27Kip1 
protein degradation (27, 28). Several studies indicate that 
S phase kinase-associated protein 2 (Skp2), an F-box protein, 
functions as the receptor component of an SCF ubiquitin 
ligase complex, binding to p27Kip1 in conjunction with CDK 
subunit 1 (Cks1) only when T187 of p27Kip1 is phosphory-
lated. This results in the ubiquitination and degradation of 
p27Kip1 (29–31).
IL-7 has been previously reported to down-regulate 
p27Kip1 in T cell acute lymphoblastic leukemia cells, and this 
was proposed to promote clonal expansion of these trans-
formed cells (32, 33). To understand how IL-7 aff  ects cell 
cycle in nontransformed T cells, we evaluated the role of 
p27Kip1 in proliferation in an IL-7–dependent thymocyte line 
and in peripheral T cells in vivo, and we observed two path-
ways, Skp2- and protein kinase C (PKC)θ-dependent, by 
which IL-7 receptor regulates p27Kip1 degradation.
RESULTS
Bcl-2 cannot replace the requirement for IL-7 
in promoting cell proliferation
IL-7 promotes survival by maintaining a favorable balance of 
Bcl-2 family members in which antiapoptotic proteins   protect 
from proapoptotic proteins. One of the actions of IL-7 is to 
induce the synthesis of the antiapoptotic protein Bcl-2 (10), 
and transgenic expression of bcl-2 has been shown to par-
tially overcome the requirement for IL-7 for thymopoiesis 
(34). Although thymopoiesis requires both cell survival and 
proliferation, it was possible that IL-7 signaling did not in-
duce proliferation directly but blocked apoptosis, thereby per-
mitting other proliferative signals to drive the expansion of 
T cells. Because the D1 thymocyte line (35) responds to IL-7 
by survival and proliferation, we examined to what extent 
overexpression of bcl-2 could replace the IL-7 signal by stably 
transfecting D1 cells with a bcl-2 retroviral expression vector. 
As shown in Fig. 1, withdrawal of IL-7 for 24 h from un-
transfected D1 cells induced both G1 arrest and  30% of cells 
died. However, bcl-2–transfected D1 cells could survive in-
defi  nitely without IL-7 but nevertheless underwent G1 arrest. 
Restimulation of bcl-2–transfected cells with IL-7 restored a 
normal rate of proliferation (not depicted). Thus, Bcl-2 could 
replace the survival function of IL-7 but failed to replace the 
proliferative function, indicating that IL-7 induces a prolifera-
tion pathway that is distinct from the antiapoptotic pathway.
IL-7 down-regulates p27Kip1 via posttranslational regulation
Entry into S phase can be inhibited by the CKI p27Kip1, and 
it has been shown that IL-3 and IL-2 block p27Kip1 gene ex-
pression (24, 25). It was reported that in IL-7–responsive 
T cell acute lymphoblastic leukemia cells, both survival and 
cell division correlated with low levels of p27Kip1 protein 
(33). Therefore, we examined whether IL-7 infl  uenced the 
expression of p27Kip1 in D1 cells or LN T cells. Western blot-
ting analysis revealed that after IL-7 withdrawal from D1 
cells, p27Kip1 protein levels rose dramatically, whereas levels 
of another CKI, p16, remained unchanged (Fig. 2 A). p21Cip1, 
another CKI, was undetectable in D1 cells (not depicted). 
p27Kip1 protein levels also increased in primary cultures of 
T cells after 24 h of IL-7 deprivation. Both p16 and p21Cip1 
expressions were not aff  ected by IL-7 withdrawal in LN cells 
(Fig. 2 B). Overexpression of bcl-2 in D1 cells altered neither 
cell cycle status (Fig. 1) nor p27Kip1 expression (Fig. 2 C). To 
determine whether IL-7 regulated p27Kip1 at the transcrip-
tional level, we performed Northern blotting. Withdrawal of 
Figure 1.  Proliferative effect of IL-7 is independent of survival 
effect. D1 or bcl-2–transfected D1 cells were cultured in the presence or 
absence of IL-7 for different time points. Cell cycle and survival were 
analyzed by PI staining after fl  ow cytometric assay. G1 peak, S phase, 
G2/M phase, and apoptotic populations are indicated. Ap, apoptosis. 
  Percentage of cells in different populations was calculated by ModFit LT 
software. The results are representative of three independent experiments.JEM VOL. 203, March 20, 2006  575
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IL-7 from D1 cells did not increase the mRNA levels of 
p27kip1 (Fig. 2 D). Therefore, unlike IL-3 or IL-2, IL-7 
down-regulated p27Kip1 at a posttranslational level rather than 
at the transcriptional level.
p27Kip1 induces G1 arrest in D1 cells
To determine if p27Kip1 could contribute to G1 arrest after 
IL-7 withdrawal, D1 cells were transfected with p27Kip1 in a ret  -
roviral expression vector expressing GFP as a selective marker. 
20 h later, GFP+ cells were sorted and placed in culture with 
IL-7. D1 cells or p27Kip1-transfected D1 cells were stained 
with propidium iodide (PI) and cell cycle status was analyzed 
by fl  ow cytometry. As shown in Fig. 3, in the presence of 
IL-7, overexpression of p27Kip1 in D1 cells induced complete 
G1 arrest 36 h after transfection and no apoptosis was  observed. 
To determine whether p27Kip1 was required for G1 arrest after 
IL-7 withdrawal, we introduced a small interfering RNA 
(siRNA), pMIG-hU6-sip27Kip1 (sip27Kip1), to knockdown ex-
pression of endogenous p27kip1 in D1 cells. The expression of 
p27Kip1 was strongly inhibited by sip27Kip1 at 15 h after IL-7 
deprivation, whereas the control-scrambled siRNA showed 
no eff  ect (Fig. 4, top). PI staining analysis showed that cell 
  cycle progression into S phase after IL-7 withdrawal was also 
enhanced by sip27Kip1. After 15 h of IL-7 deprivation, the 
number of cells bearing sip27Kip1 in S phase increased to 
28.55%, as compared with 18.36% of that in control cells 
(Fig. 4, bottom). There was no diff  erence in cell survival 
  between D1 with sip27Kip1 and D1 with siRNA control (Fig. 4, 
bottom). These data implicate the up-regulation of p27Kip1 as 
an important mediator of G1 arrest after IL-7 withdrawal.
p27Kip1 defi  ciency partially restores T cell proliferation 
in IL-7–defi  cient hosts
Having shown that in the D1 thymic cell line p27Kip1 plays an 
important role in cell cycle arrest after IL-7 withdrawal, we 
tested this model using peripheral T cells in vivo. After trans-
fer of T cells into a host depleted of lymphocytes, the survival 
and expansion of most subsets requires IL-7 (1, 3). This is 
termed the “homeostatic” role of IL-7, distinct from the thy-
mopoietic role, enabling us to evaluate the role of p27Kip1 in 
IL-7 signaling in normal T cells. LN cells from p27Kip1 KO or 
C57BL/6 (WT) mice were labeled with CFSE and trans-
ferred into sublethally irradiated Rag−/− or IL-7−/−/Rag−/− 
recipient mice. 6 d after transfer, donor cell homeostatic pro-
liferation profi  les were analyzed by staining with anti-CD4 
or anti-CD8 followed by fl  ow cytometry. The recoveries of 
CFSE+ donor cells per mouse were as follows: 9.8 ± 2.8 × 104 
Figure 2.  IL-7 down-regulates p27Kip1 posttranslationally. (A) D1 
cells were cultured with (+) or without (−) IL-7 for 12 h. Cell lysates 
were resolved by SDS-PAGE and immunoblotted with antibodies against 
p27Kip1, p16, and β-actin. (B) LN T cells were isolated and grown with or 
without IL-7 for 24 h. Protein levels were measured by immunoblotting 
using antibodies against p27Kip1, p16, p21Cip1, and β-actin. (C) Cell lysates 
were prepared from D1 or bcl-2–transfected D1 cells cultured with or 
without IL-7 for 12 h. p27Kip1 protein level was measured by immuno-
blotting. (D) D1 cells were cultured with (+) or without (−) IL-7 for 12 h. 
Total RNAs were isolated and 20 μg total RNA was loaded to agarose 
gel (bottom). The RNA blot was probed with 32P-labeled p27Kip1 cDNA 
fragment (top).
Figure 3.  p27Kip1 causes G1 arrest without effect on survival in 
D1 cells. D1 cells were transfected with p27Kip1 and cultured with IL-7 for 
certain time points. Cell cycle and survival were analyzed by PI staining 
after fl  ow cytometric analysis. G1 peak, S phase, G2/M phase, and apop-
totic populations are indicated. Ap, apoptosis. Percentage of cells in dif-
ferent populations was calculated by ModFit LT software. The results are 
representative of three independent experiments.576  IL-7/T CELL PROLIFERATION/P27KIP1 | Li et al. 
(p27Kip1 KO into Rag−/− host), 9.0 ± 1.2 × 104 (WT 
into Rag−/− host), 4.1 ± 1 × 104 (p27Kip1 KO into IL-
7−/−/Rag−/− host), and 3.1 ± 0.9 × 104 (WT into IL-
7−/−/Rag−/− host). These recoveries of CFSE+ cells are in 
the range of 2–5% of cells transferred into IL-7–  competent 
hosts, comparable to similar published studies.
As shown in Fig. 5, the proliferation of CD8 cells was 
faster (79.6% of WT and 80.4% of p27Kip1 KO cells under-
went six divisions) compared with CD4 cells (52.2% of WT 
and 53.8% of p27Kip1 KO cells underwent three to four divi-
sions; Fig. 5, A and B). In agreement with previous studies, 
homeostatic survival and proliferation of peripheral T cells 
was dramatically reduced in IL-7−/−/Rag−/− mice (20.3% of 
CD4 and 38.9% of CD8 cells had divided), as compared with 
that in Rag−/− hosts (52.2% of CD4 and 79.6% of CD8 cells 
had divided; Fig. 5, B and D). Because cell death eventually 
occurs in the absence of IL-7, we chose an early time point 
(6 d) at which cell cycle arrest occurred in many cells before 
they died. About 20.3% of WT CD4 cells underwent just 
one division, and 38.9% of WT CD8 cells underwent two 
divisions in IL-7−/−/Rag−/− hosts (Fig. 5 D). p27Kip1 defi  ciency 
enhanced both CD4 and CD8 cell proliferation in the absence 
of IL-7. In comparison with WT cells in IL-7−/−/Rag−/− 
hosts, 42.9% of p27Kip1-defi  cient CD4 cells underwent two 
divisions, and 53.4% of p27kip1-defi  cient CD8 cells under-
went four divisions (Fig. 5, C and D). p27Kip1 defi  ciency did 
not completely replace the IL-7 signal (42.9 vs. 52.2% of pro-
liferated CD4 and 53.4 vs. 79.6% of proliferated CD8; Fig. 5, 
B and C) because it would not be expected to protect from 
apoptosis. Hence, p27Kip1 is a key negative cell cycle regula-
tor controlled by IL-7 in T cells.
IL-7–induced p27Kip1 degradation mediated by Skp2-
dependent and Skp2-independent/PKC-dependent pathways
We then investigated the molecular mechanism of IL-7–
  induced p27kip1 degradation. Phosphorylation of p27kip1 at 
threonine 187 (T187) or serine 10 (S10) has been reported 
to aff  ect its stability (36, 37). We examined whether p27Kip1 
phosphorylation is regulated by IL-7 in D1 cells. D1 cells 
were deprived of IL-7 for various times, and as shown in 
Fig. 6 A, p27Kip1 protein levels began to rise within 4 h 
and continually increased up to 12 h after IL-7 withdrawal. 
The increase in p27Kip1 correlated with its phosphorylation 
at T187, whereas its phosphorylation at S10 remained 
  unchanged (Fig. 6 A).
In the course of a previous study of cell death pathways, 
we had made the fortuitous observation that PKC inhibitors 
could aff  ect cell cycle. Several studies have shown that PKCδ 
or PKCα could inhibit cell proliferation concomitant with 
increasing p27Kip1 protein levels in some cell types (38–40). 
Therefore, we assayed the impact of PKC inhibitors on p27Kip1 
expression in D1 cells and observed that a PKC inhibitor, 
Gö6850 (inhibitor of classic and novel PKCs), blocked p27Kip1 
up-regulation and decreased phosphorylation at T187 after 
IL-7 withdrawal, whereas the classic PKC   inhibitor Gö6976 
did not (Fig. 6 B). These data suggest that one of the novel 
PKCs is activated after IL-7 withdrawal and induces the 
  accumulation of p27Kip1.
The phosphorylation of T187 rose in parallel to the rise in 
p27Kip1 protein, which was surprising because phospho-T187 
was previously implicated in destabilizing the protein (28, 
36). To examine whether T187 phosphorylation destabilized 
p27Kip1 protein in D1 cells, we generated p27Kip1 mutants. 
Replacing T187 with alanine (T187A) would prohibit phos-
phorylation, whereas replacing T187 with arginine (T187D) 
would mimic phosphorylation. FLAG-tagged p27Kip1 con-
structs (with GFP as a selective marker) were transfected into 
D1 cells, and 48 h later cell lysates were subjected to im-
munoblotting analysis with anti-FLAG and anti-GFP. The 
T187A mutant was higher than the WT protein level, sug-
gesting that phosphorylation did in fact destabilize p27Kip1. 
Confi   rming this hypothesis, mimicking phosphorylation 
in the T187D mutant reduced p27Kip1   levels. As a control, 
p27Kip1 S10A-FLAG was detected at the same level as the 
WT, and equal GFP expression refl  ected the same transfec-
tion effi   ciency (Fig. 6 C). These data suggest that phosphor-
ylation of T187 promotes p27Kip1 degradation, confi  rming 
previous studies. However, after IL-7 withdrawal, another 
mechanism (through a novel PKC) has a dominant stabilizing 
eff  ect, resulting in a rise of both phosphorylated and non-
phosphorylated p27Kip1.
Figure 4.  siRNA knockdown of p27Kip1 expression protects from 
cell cycle arrest induced by IL-7 deprivation in vitro. D1 cells trans-
fected with either pMIG-hU6-sip27Kip1 (sip27Kip1, small interfering p27Kip1) 
or pMIG-hU6-NC (Control, scrambled siRNA control) were kept in IL-7 or 
without IL-7 for 15 h. Total cell extracts were subjected to immuno-
blotting with antibodies against p27Kip1 and β-actin (top). Cell cycles were 
determined by PI staining (bottom). Percentage of cells in different popu-
lations was calculated by ModFit LT software. A representative experiment 
of three performed is shown.JEM VOL. 203, March 20, 2006  577
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T187 phosphorylation-dependent p27Kip1 degradation had 
been shown to require Skp2 and Cks1 (29, 30), and Skp2 
and Cks1 expression is growth regulated and controlled by 
growth factors (41). Therefore, we examined the expression 
of Skp2 and Cks1 and observed that both Skp2 and Cks1 
protein levels dropped after 12 h of IL-7 deprivation in D1 
cells, suggesting that their decline could at least contribute 
to some of the accumulation of p27Kip1 at later time points. 
However, the PKC inhibitor Gö6850 did not prevent the 
decline of Skp2 and Cks1 (Fig. 6 D), although it blocked 
p27Kip1 accumulation (Fig. 6 B). Thus, the PKC pathway of 
p27Kip1 protein accumulation after IL-7 withdrawal in T cells 
is not through degradation of Skp2 and Cks1.   Collectively, 
our fi  ndings indicate that two distinct mechanisms   mediate
Figure 5.  The loss of p27Kip1 compensates the loss of IL-7–
  promoting T cell proliferation in vivo. Lymphocytes were isolated 
from LNs from p27−/− or WT mice and labeled by CFSE, and then trans-
ferred intravenously into irradiated IL-7−/−/Rag−/− or Rag−/− mice. 6 d 
later, spleens and LNs were removed from recipient mice and lympho-
cytes were prepared. Donor T lymphocytes were analyzed for CFSE 
Figure 6.  Inhibition of PKC after IL-7 withdrawal blocks p27Kip1 
induction through a Skp2 and T187 phosphorylation–independent 
pathway. (A) Protein levels of p27Kip1 and phospho-p27Kip1 were mea-
sured in D1 cells. Cells were deprived of IL-7 for various time points 
and cell lysates were resolved by SDS-PAGE. Immunoblotting was per-
formed with antibodies against p27Kip1, phospho-p27Kip1 (T187 or S10), 
and β-actin. (B) The effect of PKC inhibitor on p27Kip1 stability was 
determined. IL-7 was withdrawn from D1 cells for 12 h and 5 μM of 
the PKC inhibitor Gö6850 was added at the time of IL-7 withdrawal. 
Protein levels were measured by immunoblotting using antibodies 
against p27Kip1, phospho-p27Kip1 (T187), and β-actin. 0.1% of DMSO 
was included as a negative control. (C) p27Kip1 stability affected by 
phosphorylation was analyzed in D1 cells overexpressing the FLAG-
tagged p27Kip1 WT, single mutant T187A, S10A, or T187D, respectively. 
Extrogenous protein levels were detected by immunoblotting using 
antibody against FLAG. The GFP expression level was also measured as 
transfection effi  ciency control. (D) Skp2 and Cks1 expressions were 
measured in D1 cells. Cell lysates were prepared from cells deprived of 
IL-7 for 4 and 12 h, or cells cultured without IL-7 for 12 h and 5 μM 
of the PKC inhibitor Gö6850. Immunoblotting was analyzed by specifi  c 
antibodies against Skp2, Cks1, and β-actin. 0.1% of DMSO was 
  included as a negative control.
  intensity by gating on CD4+ and CD8+ cells using fl  ow cytometry. 
  Numbers over the peaks indicate the number of cell divisions. Vertical 
line represents the gate used for calculating the percentage of cells that 
had divided, which was calculated using WinMDI software (reference 3). 
Data are representative of two experiments.578  IL-7/T CELL PROLIFERATION/P27KIP1 | Li et al. 
IL-7–induced p27Kip1 degradation in T cells: (a) Skp2-/T187 
phosphorylation-dependent pathway and (b) a pathway 
blocked by a novel PKC.
IL-7 deprivation activates PKC𝗉, and inhibition 
of PKC𝗉 prevents G1 arrest
Having observed the involvement of a novel PKC in p27Kip1 
up-regulation after IL-7 withdrawal, we then assessed which 
PKC isozyme is activated by IL-7 withdrawal. D1 cells were 
cultured with or without IL-7, and as shown in Fig. 7 A, 
PKCα, PKCβ, PKCδ, and PKCθ were present in D1 cells, 
but only PKCθ activation rose after IL-7 withdrawal. PKCθ 
activation occurred within 4 h after IL-7 withdrawal and re-
mained activated up to 12 h (Fig. 7 B). To determine if PKC 
played a key role in cell cycle arrest, D1 cells were treated 
with the PKC inhibitor Gö6850 after withdrawal of IL-7. 
By blocking PKC activation, G1 to S phase transition was re-
stored in D1 cells after withdrawal of IL-7 for 12 h (Fig. 7 C). 
The classical PKC inhibitor Gö6976 had no eff  ect  (not 
  depicted). Our fi  ndings suggest that IL-7 withdrawal acti-
vates PKCθ, which, through an unknown mechanism, stabi-
lizes p27Kip1 protein that in turn induces G1 arrest.
DISCUSSION
T lymphocytes depend on IL-7 for survival and homeostatic 
proliferation. The survival function of IL-7 is largely through 
maintaining a favorable balance of Bcl-2 family members. 
Here we show that IL-7 stimulates proliferation indepen-
dently of survival and evaluate the role of the CKI p27Kip1. 
We show that withdrawal of IL-7 induced G1 arrest and 
up-regulated p27Kip1. Overexpression of p27Kip1 induced G1 
arrest in the presence of IL-7, and deletion of p27Kip1 partially 
replaced IL-7 in supporting T cell proliferation both in a cell 
line and in normal T cells in vivo. IL-7–induced p27Kip1 deg-
radation involved two distinct mechanisms: the conventional 
Skp2-/T187 phosphorylation-dependent pathway and a Skp2-
independent/PKCθ-dependent pathway that appeared to be 
the dominant mechanism. Fig. 8 illustrates one possible model 
that incorporates these hypotheses.
IL-7 induces synthesis of Bcl-2 both in pro–T cells (10, 42) 
and mature T cells (3, 43). Protection of T cells from death is 
the major function of Bcl-2, although other studies have shown 
an antiproliferative eff  ect in T cells (44, 45). However, analysis 
of bcl-2–transgenic mice showed that Bcl-2 inhibited prolif-
eration of T cell progenitors in response to signals from the 
pre-TCR but not the IL-7 receptor (45). We also observed that 
Bcl-2 prevented D1 cell death from the loss of IL-7 (Fig. 1) but 
did not inhibit proliferation in the presence of IL-7 (Fig. 1). 
Transgenic expression of Bcl- 2 in IL-7R−/− mice rescued T 
lymphopoiesis (34, 46), suggesting that survival but not prolif-
eration is the major function of IL-7 in T cell development. 
However, IL-7 is also required for homeostatic proliferation of 
mature T cells, and a bcl-2 transgene did not replace this IL-7 
function (1). We have confi  rmed that a bcl-2 transgene pro-
tected T cells from death after transfer into an IL-7−/− host but 
did not restore the capacity to proliferate (unpublished data). 
Thus, IL-7 receptor delivers a proliferative eff  ect that is distinct 
from the survival eff  ect involving Bcl-2 family members.
Figure 7.  PKC𝗉 is activated and inhibition of PKC𝗉 prevents cell 
cycle G1 arrest after IL-7 withdrawal. (A) PKC activation was analyzed 
in D1 cells of IL-7 withdrawal for 12 h. Cell lysates were resolved by SDS-
PAGE and immunoblotted using a phospho-PKC sample kit. Total PKCθ 
was measured as a loading control. (B) PKCθ activation was determined in 
D1 cells after IL-7 deprivation. Cell lysates were made from cells deprived 
of IL-7 for 4, 8, and 12 h, and PKCθ activation was assayed by immuno-
blotting using an antibody specifi  c for PKCθ phosphorylation at threonine 
538. (C) D1 cells were cultured without IL-7 and treated with 5 μM 
Gö6850 for 15 h. Cell cycle was analyzed by PI staining and the percent-
age of cells in different populations was calculated by ModFit LT software. 
Results were pooled from three experiments.JEM VOL. 203, March 20, 2006  579
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Several studies have suggested that p27Kip1 limits T cell 
proliferation because there are more cycling thymocytes and 
peripheral T cells in p27Kip1−/− mice (19–22). We examined 
several CKIs and found that p27Kip1 was down-regulated 
by IL-7 in D1 cells (Fig. 2 A) and primary T cells (Fig. 2 B). 
Regulation of p27Kip1 levels is primarily posttranslational in 
most cell types (27, 28, 47). Although there are also reports 
of transcriptional induction after cytokine withdrawal from 
hematopoietic cell lines (24, 25), we did not observe p27Kip1 
mRNA induction by IL-7 withdrawal in D1 cells (Fig. 2 D). 
FoxO3 has been implicated in p27Kip1 gene induction by IL-2 
or IL-3 withdrawal; however, we did not observe FoxO3 
activation by IL-7 withdrawal (unpublished data), consistent 
with the observed posttranslational mechanism.
Because phosphorylation of p27Kip1 at T187 by CDK1 
or CDK2 has been shown to induce p27Kip1 degradation 
in other cell types (29, 30, 36), it was unexpected that 
  phosphorylation accompanied the increase in protein lev  -
els after IL-7   withdrawal (Fig. 6, A and B). We verifi  ed 
that phosphorylation of T187 can also destabilize p27Kip1 
in the IL-7–dependent cell line used in our studies (Fig. 6 C). 
Perhaps the observed phosphorylated p27Kip1 is either on 
the way to degradation or is in an intracellular compart-
ment lacking the machinery to degrade it, or that another 
stabilization mechanism protects it from degradation. As 
will be discussed, the major p27Kip1 degradation pathway 
regulated by IL-7 in these cells appears do be unrelated to 
T187 phosphorylation.
Embryonic fi  broblasts from T187A p27Kip1 knockin mice 
retained some capacity to degrade p27Kip1 after serum starva-
tion in embryonic fi  broblasts (48). In CD4 T cells from these 
mice, although the ability of TCR signals to induce p27Kip1 
breakdown was lost, high levels of IL-2 induced degradation 
of p27Kip1, suggesting the existence of a T187-independent 
pathway. Thus, IL-7 could induce a T187 phosphorylation-
independent pathway, eliminating p27Kip1 in cycling T cells.
Phosphorylation of p27Kip1 at T187 has been shown to be 
required for Skp2-mediated p27Kip1 proteolysis (29), which 
also requires Cks1 association with Skp2 (30, 31). However, 
analysis of p27Kip1 ubiquitination in lymphocytes from Skp2−/− 
revealed a second pathway that was independent of Skp2 and 
T187 phosphorylation (49). Both pathways may be operating 
in the IL-7 response. IL-7 withdrawal eventually decreased 
both Skp2 and Cks1 expression (Fig. 6 D), and T187 phos-
phorylation somewhat destabilized p27Kip1 in D1 cells (Fig. 
6 C). However, a PKC inhibitor prevented p27Kip1 protein 
accumulation despite the decline in Skp2 and Cks1 after IL-7 
withdrawal (Fig. 6, B and D), suggesting an independent 
pathway. The latter appears the more dominant pathway be-
cause the PKC inhibitor was suffi   cient to relieve cell cycle 
arrest in the absence of IL-7 (Fig. 7).
Among the PKC isoforms, we observed that PKCθ was 
activated after IL-7 withdrawal and inhibition of PKCθ ac-
tivity prevented cell cycle arrest (Fig. 7). PKCθ is predomi-
nantly expressed in T cells and promotes T cell proliferation 
induced by TCR and CD28 engagement (50). Our fi  ndings 
in the IL-7 pathway suggest that PKCθ can also block T cell 
proliferation by stabilizing p27Kip1 protein via a Skp2-inde-
pendent mechanism. Because p27Kip1 lacks a consensus PKCθ 
target site, we hypothesize a novel intermediate that stabilizes 
p27Kip1 (Fig. 8).
In the IL-7 pathway, one candidate for conjugating ubiq-
uitin to p27Kip1 is a newly identifi  ed ubiquitin-conjugating 
complex, Kip1 ubiquitination-promoting complex (KPC)1 
and KPC2 (51, 52). This complex has been shown to induce 
breakdown of p27Kip1 during G1 phase in embryonic fi  bro-
blasts. The mechanism for regulating KPC during cell cycle 
is diff  erent from Skp2/Cks1, which is ubiquitinated and de-
graded in S-G2 phase. KPC is located in the cytosol where 
its levels remain constant throughout the cell cycle. During 
G1 phase, p27Kip1 is exported from the nucleus and targeted 
for degradation by KPC in the cytosol. IL-7 stimulation 
could therefore induce nuclear export of p27Kip1- and KPC-
targeted degradation if it uses the mechanism of serum stimu-
lation of embryonic fi  broblasts. Alternatively, IL-7 stimulation 
could block nuclear import of human p27Kip1, which can be 
phosphorylated in its nuclear localization sequence by AKT 
(53–55); however, murine p27Kip1 lacks this site.
Our evidence suggests that Skp2/Cks1 is not the major 
pathway from IL-7 receptor to p27Kip1 degradation. This is rel-
evant to a recent report that Skp2/Cks1 induces degradation 
not only of p27Kip1, but also of Rag2 (56), which is required for 
VDJ recombination in developing thymocytes. If IL-7 were to 
induce Skp2/Cks1, then Rag2 would degrade and interrupt 
Figure 8.  Model: IL-7 regulation of p27Kip1 degradation in T cells. 
Top: In the presence of IL-7, the major pathway to p27Kip1 degradation 
is shown on the left and involves an unknown ubiquitin E3 ligase complex, 
possibly KPC1 and KPC2. The minor pathway on the right is the conven-
tional Skp1/Cks1 pathway and depends on phosphorylation of T187. 
  Bottom: In the absence of IL-7, PKCθ is activated, inactivating the major 
p27Kip1 degradation pathway and resulting in p27Kip1 accumulation. The 
minor pathway of degradation is inactivated later and also contributes to 
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VDJ recombination, whereas the opposite is actually observed: 
IL-7 is required for VDJ recombination of the TCR-γ locus 
and facilitates rearrangement of other loci (57).
We recently reported that another proliferative pathway 
is regulated by IL-7 (58). The phosphatase Cdc25a removes 
an inhibitory phosphate from the active site of CDK2, and 
we observed that after IL-7 withdrawal, Cdc25a degrades 
downstream of a stress response. Thus, IL-7 stimulates CDK2 
by two mechanisms: one by removing an inhibitory phos-
phate, and second, as reported here, by degrading an inhibi-
tor, p27Kip1. We have shown that both of these mechanisms 
are functionally important in normal T cells in that prolifera-
tion is induced, in the absence of IL-7, by introducing either 
a Cdc25a mutant that does not degrade or, as shown here, by 
eliminating p27Kip1. These studies show that cell cycle regula-
tion in lymphocytes can involve mechanisms that diff  er con-
siderably from those in cell types previously studied, such as 
fi  broblasts, and suggest that other proliferative stimuli in lym-
phocytes, in addition to IL-7, should be examined.
MATERIALS AND METHODS
Mice. p27Kip1-defi  cient  (p27−/−) mice (21), originally on a background 
mix of 129 and C57BL/6, were backcrossed onto C57BL/6 and main  -
tained by heterozygous breeding. IL-7−/−/Rag−/− mice were obtained from 
R. Murray (EOS Biotechnology, San Francisco, CA). Rag−/− mice were 
purchased from The Jackson Laboratory. Both IL-7−/−/Rag−/− and Rag−/− 
mice are maintained by homozygous breeding at the National Cancer 
  Institute (NCI), Frederick Cancer Research and Development Center 
  animal facility. NCI-Frederick Animal Care and Use Committee approved 
all experiments on mice.
Cell lines. The IL-7–dependent thymocyte cell line D1 was generated from 
p53 KO mice (35). D1 cells were maintained in RPMI 1640 supplemented 
with 10% fetal bovine serum (Hyclone), 2 mM l-glutamine, 1% penicillin-
streptomycin, 50 μM β-mercaptoethanol (Invitrogen), and 50 μg/ml 
murine recombinant IL-7 (PeproTech). Transfection used the retrovirus 
packaging cell line phoenix-Eco, maintained in DMEM supplemented with 
10% FBS, 1% penicillin-streptomycin. The PKC inhibitors Gö6850 and 
Gö6976 were purchased from CalBiochem.
DNA constructs and retroviral infection. The retroviral vector pMIG 
containing EGFP as marker and human bcl-2 retroviral expression vector 
was described previously (13). Mouse p27Kip1 cDNA construct pRC-
p27Kip1 was provided by P. Coff  er (University Medical Center, Utrecht, 
Netherlands; reference 24). The full-length p27Kip1 WT, mutant p27kip1 
T187A, T187D, and S10A cDNAs with FLAG epitope tags in the COOH 
terminus were amplifi  ed by PCR from pRC-p27Kip1 and cloned into the 
retroviral vector pMIG.
Individual retroviral constructs were transfected into the phoenix-Eco 
package cell line using Fugene-6 reagent (13). The retrovirus-containing 
  supernatants were harvested after 48 h and loaded onto a RetroNectin 
  (TaKaRa)-coated plate, and then D1 cells were added and infected  overnight. 
GFP+ cells were sorted and analyzed.
Antibodies and immunoblotting. Rabbit anti–p27Kip1, phospho-PKC 
antibody sampler kit, and goat anti–mouse IgG and goat anti–rabbit IgG 
coupled to horseradish peroxidase were purchased from Cell Signaling 
  Biotechnology. Rabbit anti–phospho-T187–p27Kip1 was from CalBiochem. 
Mouse anti–PKCθ (E-7) and rabbit anti–p16 were obtained from Santa Cruz 
Biotechnology, Inc. Rabbit anti–phospho-S10–p27Kip1, mouse anti–Skp2, 
and rabbit anti–Cks1 were from Zymed Laboratories. Mouse anti–FLAG 
and mouse anti–GFP were from Stratagene. Mouse anti–p21 was purchased 
from BD Biosciences. 5 × 106 cells were lysed in Triton X-100 lysis buff  er 
supplemented with protease inhibitor cocktails (Roche). 50 μg of protein 
lysates was resolved by SDS-PAGE on 12% Tris-Glycine gels (Invitrogen) 
and transferred to nitrocellulose membranes. Blots were probed with specifi  c 
primary antibodies, followed by the appropriate secondary antibodies conju-
gated to horseradish peroxidase and then visualized by chemiluminescence. 
The chemiluminescent Western detection kit was purchased from Roche.
Retrovirus-mediated siRNA. The DNA nucleotides encoding mouse 
p27Kip1 siRNA (GenBank accession no. U09968, nucleotide 175–195) were 
ligated into pSilence 2.1-U6 hygro (Ambion) under the expression of the 
  human U6 promoter according to the manufacturer’s protocol. The DNA 
fragment containing human U6/p27Kip1 siRNA was amplifi  ed by PCR and 
  ligated into the SalI site of the retroviral vector pMIG to generate pMIG-hU6-
sip27Kip1. D1 cells were infected twice with pMIG-hU6-sip27Kip1 retrovirus 
and GFP+ cells were sorted after 24 h of infection. Western blotting and PI 
staining were performed to analyze p27Kip1 protein expression and cell cycle.
Cell cycle analysis. Cell cycle was determined by PI staining as described 
previously (35). In brief, cells were placed in detergent buff  er containing 
50 μg/ml RNase A (Roche) at a concentration of 1–2 × 106 cells/ml, and 
then mixed with an equal volume of PI (50 μg/ml; Sigma-Aldrich) and in-
cubated at room temperature in the dark for 1 h. DNA contents were as-
sayed by fl  ow cytometry. Data were analyzed using ModFit LT software.
CFSE labeling and adoptive transfer of T cells. LNs from p27Kip1 KO 
or WT mice were homogenized in RPMI 1640 containing 5% FBS and 
  fi  ltered through a 100-μm mesh nylon screen (BD Falcon). Red blood cells 
were   removed with treatment by ACK lysing buff  er (BioSource). LN cells 
were   resuspended in PBS containing 5% FBS and warmed to 37°C, and then 
incubated for 10 min with 5 μM CFSE (Invitrogen) followed by two washes 
with PBS. 2–5 × 106 CFSE-labeled cells were suspended in PBS and adop-
tively transferred into IL-7−/−/Rag−/− or Rag−/− recipient mice by intra-
venous   injection. The recipient mice received whole body γ-irradiation 
(600 Rd) at least 3 h before the injection. 6 d later, the host mice were killed 
and LN and spleen cells were stained with PE-Cy5–conjugated anti-CD4 
(BD Biosciences) or PE-Cy5–conjugated anti-CD8 (BD Biosciences). The 
intensity of CFSE on donor cells was analyzed by gating on either CD4+ or 
CD8+ on a FACScan fl  ow cytometer.
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